MoonLake Immunotherapeutics (MLTX)
| Previous Close | 48.16 |
| Open | 47.70 |
| Bid | 47.00 x 100 |
| Ask | 47.45 x 100 |
| Day's Range | 46.54 - 48.61 |
| 52 Week Range | 35.11 - 64.98 |
| Volume | |
| Avg. Volume | 340,515 |
| Market Cap | 2.979B |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.87 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.87 |
Simply Wall St.We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswireMoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody? sonelokimab in hidradenitis suppurativa (“HS”), with topline results anticipated as of mid-2025Secured positive feedback from both U.S. Food and Drug Administration (“FDA”) and the E.U. European Medicines Agency (“EMA”) on the regulatory path for the Phase 3 program of the Nanobody? sonelokimab in psoriatic arthritis (“P
- GlobeNewswire
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody? sonelokimab in Psoriatic Arthritis
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody? sonelokimab in Psoriatic Arthritis Builds upon the positive regulatory feedback received from FDA and EMA on Phase 3 VELA program for sonelokimab in hidradenitis suppurativa (HS), which has started recruitmentClarified path for PsA Phase 3 program with study design, patient population and endpoints agreed – program is called IZAR and two trials are planned wi
